A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer

After androgen deprivation therapy, a significant number of prostate cancer cases progress with a therapy-resistant neuroendocrine phenotype (NEPC). This represents a challenge for diagnosis and treatment. Based on our previously reported design of theranostic small-molecule prodrug conjugates (T-SM...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Paulina, Debnath, Sashi, Chen, Yu-An, Hernandez, Elizabeth, Jha, Preeti, Dakanali, Marianna, Hsieh, Jer-Tsong, Sun, Xiankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967013/
https://www.ncbi.nlm.nih.gov/pubmed/36839802
http://dx.doi.org/10.3390/pharmaceutics15020481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967013/
https://www.ncbi.nlm.nih.gov/pubmed/36839802
http://dx.doi.org/10.3390/pharmaceutics15020481

Ejemplares similares